Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC

Core Viewpoint - Entero Therapeutics has signed a rescission agreement with all previous shareholders of ImmunogenX, which allows the company to unwind a previously announced business combination, thereby strengthening its balance sheet and refocusing its strategic initiatives [1][2]. Group 1: Rescission Agreement - The rescission agreement involves 100% of the previous shareholders of ImmunogenX and is subject to certain closing conditions, including shareholder approval by June 30, 2025 [1]. - The decision to execute the rescission agreement is aimed at providing Entero and ImmunogenX the flexibility to pursue their respective strategic initiatives while maintaining a positive working relationship [2]. Group 2: Leadership Changes - Anna Skowron has been appointed as the Chief Financial Officer of Entero effective March 3, 2025, bringing over 14 years of accounting experience and expertise in financial reporting, compliance, and corporate governance [2]. Group 3: Company Overview - Entero Therapeutics is a late clinical-stage biopharmaceutical company focused on developing targeted, non-systemic therapies for gastrointestinal diseases, addressing significant unmet needs in GI health [4]. - The company's key programs include latiglutenase for celiac disease, capeserod for gastroparesis, and adrulipase for patients with exocrine pancreatic insufficiency [4].